Get the Stockscreener App
8.12
3.79%
-0.32
After Hours:
8.25
0.13
+1.60%
Passage Bio Inc stock is traded at $8.12, with a volume of 56,238.
It is down -3.79% in the last 24 hours and down -10.87% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$8.44
Open:
$8.29
24h Volume:
56,238
Relative Volume:
0.99
Market Cap:
$25.81M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-6.9402
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
-6.24%
1M Performance:
-10.87%
6M Performance:
+13.09%
1Y Performance:
+1,627%
1-Day Range:
$7.70
$8.61
1-Week Range:
$7.70
$9.12
52-Week Range:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.12 | 26.83M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Buyout Rumor: Should I invest in Passage Bio Inc before earningsInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Coverage Initiated by Analysts at Chardan Capital - Defense World
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 - Defense World
Retail Surge: What is the dividend yield of Passage Bio Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Ideas: Can Passage Bio Inc. reach all time highs this yearQuarterly Portfolio Summary & Long-Term Growth Plans - mfd.ru
Gm1 Gangliosidosis Treatment Market Witness Booming Growth: - openPR.com
Earnings Miss: Is PAYC stock a buy or sellTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Gap Down: How does Passage Bio Inc perform in inflationary periodsWeekly Stock Summary & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Analyst Calls: Is Information Services Group Inc likely to announce a buyback2025 Risk Factors & High Conviction Buy Zone Picks - baoquankhu1.vn
Market Rankings: Why is Royce Small Cap Trust Inc stock going downProduct Launch & Low Drawdown Investment Ideas - baoquankhu1.vn
Insider Trends: Is TETRA Technologies Inc. a cyclical or defensive stockMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Death Cross: Why is Peloton Interactive Inc stock going up2025 Fundamental Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Is Cardlytics Inc. stock overvalued by current metrics2025 Risk Factors & Accurate Technical Buy Alerts - bollywoodhelpline.com
Aug Volume: Is RYAAY stock forming a cup and handleAnalyst Downgrade & Risk Managed Investment Strategies - baoquankhu1.vn
US Market Wrap: How do insiders feel about VSCOJuly 2025 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Is Passage Bio Incs ROIC above industry averageEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Sentiment Watch: Does Passage Bio Inc have pricing powerJuly 2025 Snapshot & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Institution Moves: Will NVEC stock reach all time highs in 20252025 Growth vs Value & Daily Market Momentum Tracking - Bộ Nội Vụ
Insider Selling: Passage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in Stock - MarketBeat
Passage Bio, Inc. (NASDAQ:PASG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Does Passage Bio Inc. stock trade at a discount to peers2025 Macro Impact & Real-Time Chart Breakout Alerts - Улправда
Why BTSG stock is rated strong buyMarket Volume Summary & Consistent Profit Focused Trading Strategies - Улправда
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):